Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Ascletis’ rival to Lilly’s Foundayo hits diabetes trial goals
A phase 2 trial of Ascletis’ oral GLP-1 candidate has hit its primary and secondary endpoints, teeing up a two-front attack on Eli Lilly’s Foundayo.
Nick Paul Taylor
Oct 29, 2026 5:11am
Lilly’s retatrutide tops Ozempic in ph. 3 diabetes showdown
Oct 28, 2026 7:45am
Zealand, Roche’s ‘intriguing’ weight loss soured by blood sugar
Oct 8, 2026 4:34am
Zealand slides as Boehringer-partnered obesity drug underwhelms
Oct 1, 2026 6:15am
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
Sep 30, 2026 1:52pm
Lilly sets up next-gen obesity war with phase 3 retatrutide data
Sep 30, 2026 3:06am